Twist Bioscience Corporation announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. In addition, Patrick Weiss will step down from his role as chief operating officer into a strategic advisor role for personal reasons, effective April 21, 2022, while a formal search is conducted for his replacement. Mr. Weiss is expected to remain with the Company for a period of time to facilitate the transition of his duties while the Company conducts a search for his replacement.

Tracey joined Twist through the acquisition of Abveris, in November 2021. Prior to Twist, she served as CEO of Abveris. Tracey initially served as Abveris' chief operating officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns.

Nimisha joined Twist in March 2014 and was instrumental in automating processes and procedures to fuel the growth of Twist into a leading global manufacturer of synthetic DNA. She built out the core technology team and scaled up key laboratory processes, workflows and automation, which enabled the high-throughput production of novel synthetic DNA-based offerings. Prior to joining Twist, Nimisha held key technical and leadership positions at various startups as well as academic and national laboratories where she drove the development and scale up of microfluidics technologies for multiplexed pathogen detection and in vitro diagnostics.